Clinical practice guideline: Smoking cessation in chronic obstructive pulmonary disease - An effective medical intervention;Klinische leitlinie: Tabakentwöhnung bei chronisch obstruktiver lungenerkrankung - Eine effektive und sinnvolle medizinische intervention

Deutsches Arzteblatt

Volumn 106, Issue 16, 2009, Pages 276-282

  Andreas, Stefan ^a   Hering, Thomas ^b   Mühlig, Stephan ^c   Nowak, Dennis ^d   Raupach, Tobias ^e   Worth, Heinrich ^f  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Pneumologe   (Germany)

^c CHEMNITZ UNIVERSITY OF TECHNOLOGY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f KLINIKUM FÜRTH   (Germany)

Author keywords

Addiction; Chronic obstructive pulmonary disease; Evidence based medicine; Nicotine withdrawal; Smoking

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE PATCH; TOBACCO SMOKE; VARENICLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COUGHING; DISEASE EXACERBATION; DIZZINESS; DRUG DEPENDENCE; DYSPNEA; EPILEPSY; EVIDENCE BASED MEDICINE; FLATULENCE; HEADACHE; HEALTH CARE COST; HEARTBURN; HUMAN; INSOMNIA; LUNG DISEASE; LUNG FUNCTION; MEDICAL EXPERT; MEDICAL SOCIETY; MORTALITY; MOTIVATION; MOUTH DISEASE; MUCOSA INFLAMMATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; PASSIVE SMOKING; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; QUESTIONNAIRE; REVIEW; RISK REDUCTION; SEIZURE; SKIN MANIFESTATION; SLEEP DISORDER; SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE; VERTIGO; VIVID DREAM; VOMITING; XEROSTOMIA;

EID: 69049119179     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0276     Document Type: Review

References (25)

1. Tonnesen P, Carrozzi L, Fagerstrom KO, Gratziou C et al.: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417. (Pubitemid 46231920)
2. Janson C, Künzli N, deMarco R al.: Change in active and passive smoking in the EU respiratory health survey. Eur Respir J 2006; 27: 517-524
3. Nelson CB, Wittchen HU: Smoking and nicotine dependence. Results from a sample of 14- to 24-year-olds in Germany. Eur Addict Res 1998; 4: 42-49
4. Center disease control: Cigarette smoking among adults-United States, 1995. MMWR Morb Mortal Wkly Rep 1997; 46: 1217-1220
5. ASPECT Consortium: Tobacco or health in the European Union. Belgien: European Commission 2004; 1-295.
6. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years' observations on male British doctors. Bmj 2004; 328: 1519. (Pubitemid 38850305)
7. Lokke A, Lange P, Scharling H, Fabricius P et al.: Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939 (Pubitemid 44787161)
8. Shahab L, Jarvis MJ, Britton J,West R: Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61: 1043-1047 (Pubitemid 44852021)
9. Crieé C-P, Novak D: Einsparpotential durch Prävention bei COPD, in Zukunft sichern. In: Schauder P et al. (editors): Senkung der Zahl chronisch Kranker, Verwirklichung einer realistischen Utopie. Köln: Deutscher Ärtzeverlag 2006; 205-208
10. Phillips B, Ball C, Sackett D: Levels of evidence, www.cebm.net/ index.aspx?o=1025. 2001, Oxford Centre for Evidence-based Medicine.
11. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV): Nationales Programm für Versorgungs- Leitlinien. Methoden-Report 2004.
12. Andreas S, Batra A, Behr J et al.: Tabakentwöhnung bei COPD. S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie 2008; 62: 255-272
13. Fidler JA,Wardle J, Brodersen NH, Jarvis MH et al.: Vulnerability to smoking after trying a single cigarette can lie dormant for three years or more. Tob Control 2006; 15: 205-209
14. Andreas S, Anker SD, Scanlon PD: Somers VK, Neurohumoral activation as a link to systemic manifestation of chronic lung disease. Chest 2005; 128: 3618-3624
15. Fletcher C, Peto R, The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648 (Pubitemid 8124466)
16. Lifting the smoke screen-10 reasons for a smoke free Europe. Brussels: European Respiratory Society 2006; 28 ff.
17. Batra A, Lindinger P, Schütz C: Tabakbedingte Störungen " Leitlinie Tabakentwöhnung". Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften 2004.
18. Fiore MC: Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45: 119.
19. Anthonisen NR, Skeans MA, Wise RA, Manfreda J et al.: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239 (Pubitemid 40216240)
20. Wagena EJ, Zeegers MP, van Schayck CP,Wouters EF: Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003; 26: 381-403. (Pubitemid 36560712)
21. van der Meer RM,Wagena EJ, Ostelo RW, Jacobs JE et al.: Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003: CD002999.
22. Silagy C, Lancaster T, Stead L, Mant D et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004: CD000146.
23. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007: CD006103.
24. Wagena EJ, Knipschild PG, Huibers MJH,Wouters EFM, et al.: Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 2286-2292 (Pubitemid 41549926)
25. Felten D, Raupach T, Sessler C, Lüthje L et al.: Efficacy of a cognitivebehavioral program with pharmacological support to achieve smoking cessation. Dtsch Med Wochenschr 2006; 131: 197-202. (Pubitemid 43265374)